Latest News

We are excited to launch a new blog series where we talk to members of our more than 400- strong team about why they enjoy their role at Simbec-Orion. We previously spoke with Dr Maria Kozlak on a day in the life of a CRA. This month we are speaking with Tracy Thomas, Head of […]

Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having recently undergone FDA approval, Lupuzor™ is commencing into phase 3 clinical trials. Simbec-Orion are proud to have been selected by ImmuPharma as a partner to conduct the international phase 3 trial of Lupuzor™ involving pharmacokinetic […]

Simbec-Orion recently helped a biotech sponsor demonstrate the safety and tolerability of a new trial treatment for idiopathic pulmonary fibrosis (IPF). Devising an effective umbrella trial design adapted to the needs of IPF patients, we were able to deliver final CSR results ahead of time. Our researchers devised and conducted the umbrella study design testing […]

A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered dose inhaler in patients with moderate‑to‑very severe chronic obstructive pulmonary disease. Simbec-Orion worked with two leading organisations, Astra Zeneca and Cardiff Scintigraphics, to successfully complete a scintigraphy study in COPD patients. About the COPD study Study Title A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered […]

As a CRO specialising in clinical trials for rare and orphan diseases, Rare Disease Day has become a special cause to us. This year we wanted to give something back to the rare disease patient community and offer our employees the chance to get their families involved in some creative fundraising activities. Inspired by 2021’s […]

Rare Disease Day offers a valuable opportunity to raise awareness of rare disease and campaign for health equity. We are delighted to take part in Health Awareness’ Rare Diseases campaign this year, which in addition to our own contribution, features articles from Genetic Alliance UK, Rare Diseases International and EURORDIS to offer a diverse range […]

We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.